Oral Systemic Medications for Psoriasis
Methotrexate is the recommended first-line oral systemic medication for moderate to severe psoriasis, with a typical dosage of 7.5-25 mg weekly, administered orally or subcutaneously. 1
Primary Recommendation: Methotrexate
The 2020 Joint AAD-NPF Guidelines provide a Grade A recommendation for methotrexate in treating moderate to severe psoriasis in adults 1. This represents the strongest evidence-based recommendation among oral systemic therapies.
Dosing and Administration
- Standard dose range: 7.5-25 mg weekly 1
- Route options: Oral or subcutaneous (SC route shows superior efficacy for achieving PASI75 and PASI90 responses with fewer adverse events) 2
- Consider a test dose in patients with impaired kidney function 1
- Mandatory folic acid supplementation to reduce GI and hepatic adverse effects (though large doses may reduce methotrexate efficacy) 1
Monitoring Requirements
Baseline assessment:
- Noninvasive liver fibrosis assessment (NOT liver biopsy)
- Screen for hepatotoxicity risk factors: diabetes, obesity, nonalcoholic fatty liver disease, alcohol use >1 drink/day for women or >2 drinks/day for men, hepatitis B/C, family history of inheritable liver disease 1
Ongoing monitoring:
- Liver function tests every 3-6 months
- For abnormal elevations: repeat in 2-4 weeks; if persistent, refer to GI
- Annual hepatology referral or transient elastography if baseline abnormalities present 1
Alternative Oral Agents
Cyclosporine
- Use for: Rapid disease control (faster onset than methotrexate)
- Limitation: Not suitable for long-term use due to nephrotoxicity and hypertension risk
- Contraindications: Renal insufficiency, uncontrolled hypertension, prior PUVA treatment, systemic malignancy 1
Acitretin
- Particularly effective for: Erythrodermic psoriasis, generalized pustular psoriasis, palmoplantar psoriasis (84% improvement rate in pustular variants) 1
- Dose range: 10-50 mg daily 1
- Major advantage: Not immunosuppressive 1
- Critical limitation: Women cannot consider pregnancy for 3 years after discontinuation 1
- Combination benefit: Can reduce phototherapy doses by 30-50% when combined with UVB 1
Apremilast (Phosphodiesterase-4 Inhibitor)
- FDA-approved for psoriasis 3
- Recent trend data: Now prescribed to 52.5% of patients starting oral therapy, largely replacing cyclosporine and acitretin due to superior safety profile 4
- Advantage: Better continuation rates than cyclosporine 4
Tofacitinib (JAK Inhibitor)
- NOT FDA-approved for psoriasis (approved only for rheumatoid arthritis, psoriatic arthritis, ulcerative colitis) 1
- Off-label dosing: 5 mg or 10 mg twice daily 1
- Critical safety requirements before initiation 1:
- Lymphocyte count must be ≥500 cells/mm³
- Absolute neutrophil count ≥1000 cells/mm³
- Hemoglobin ≥9 g/dL
- Mandatory: Shingrix vaccination before starting 1
- Cannot combine with: Azathioprine, cyclosporine, or biologics 1
Clinical Decision Algorithm
For moderate to severe plaque psoriasis:
- Start with methotrexate (Grade A evidence) unless contraindicated 1
- Choose subcutaneous over oral route when possible for better efficacy and tolerability 2
- Screen for hepatotoxicity risk factors before initiating 1
Consider alternatives when:
- Acitretin: Patient has pustular/erythrodermic variants, or needs non-immunosuppressive option 1
- Apremilast: Patient prioritizes safety profile over maximal efficacy 4
- Cyclosporine: Need rapid control for acute flare (short-term only) 1
Critical Pitfalls to Avoid
- Do NOT perform baseline liver biopsy for methotrexate—use noninvasive fibrosis assessment instead 1
- Do NOT combine acitretin with tetracyclines (both increase intracranial pressure) 1
- Do NOT prescribe tofacitinib without checking baseline cell counts and ensuring proper vaccinations 1
- Do NOT forget the 3-year pregnancy restriction with acitretin in women of childbearing potential 1
- Methotrexate is less effective than biologics (adalimumab, infliximab) for cutaneous psoriasis—consider biologics if inadequate response 1